In April 2008, we entered into an asset transfer agreement with Pfizer pursuant to which we acquired all intellectual property owned by Pfizer relating exclusively to the bempedoic acid program.
Reciprocal relationship from PFE graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from PFE grap…
Reciprocal relationship from ORANY graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ESPR graph: . We maintain oversight of our ve…
. We maintain oversight of our vendors with access to our information technology resources through the inclusion of contractual security requirements as appropriate. Our cybersecurity approach is des…
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: se of these systems. Likewise, in the U.S., several states, including Colorado and California, passed laws that will…
se of these systems. Likewise, in the U.S., several states, including Colorado and California, passed laws that will take effect in 2026, to regulate various uses of artificial intelligence, includin…
Pursuant to the Purchase Agreement, the Company sold to the Purchaser, and the Purchaser purchased for $50,000,000, a portion of the royalties payable to the Company
the equityholders of Corstasis will be entitled to receive: (i) milestone payments up to an aggregate amount equal to $180,000,000 in the event certain regulatory approval or commercial sales milesto…
The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies for NEXLETOL and NEXLIZET. The Company's net product sales are with these customers.
On January 2, 2019, we entered into a license and collaboration agreement, or LCA, with DSE. Pursuant to the agreement, we have granted DSE exclusive commercialization rights to bempedoic acid and th…
Esperion continues to expect its partner in Israel, Neopharm Israel, to receive regulatory approval to market NEXLETOL and NEXLIZET in the first half of 2026
Reciprocal relationship from ORANY graph: Reciprocal relationship from ESPR graph: ll receive tiered royalties of five percent ( %) to twenty percent ( %) of net sales in the DS Territory. F-17 Table…
ll receive tiered royalties of five percent ( %) to twenty percent ( %) of net sales in the DS Territory. F-17 Table of Contents Esperion Therapeutics, Inc. Notes to Financial Statements (Continued) …
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYN…
and commercialization objectives. We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our cons…
Esperion Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ESPR-DEBT-9364
Warrants outstanding: 36964286
90%
xbrl warrant detail from xbrl 2025-12-31.
ESPR-DEBT-9365
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2026-03-31.
ESPR-DEBT
Debt stack $543.8M
90%
Market cache reports total debt of $543.8M.
Esperion Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Esperion Therapeutics, Inc..
Esperion Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ESPR-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 208 tracked holders.
Esperion Therapeutics, Inc. Extended Supply Chain Network
